Gut microbiota in T2DM patients on dapagliflozin therapy
36 fecal samples from type 2 diabetes mellitus patients treated with the SGLT2 inhibitor dapagliflozin (10 mg/day) in an 8-week single-arm intervention trial; location not reported. machine-written summary
36 samples · 36 runs · Age unknown · 2025 · 6.02 Gbp / sample
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 108 sample values (health condition, health condition detail, subject id) |
| ○ Abstract / description | read; no usable statement |
| ○ Full text | read; no usable statement or table · PMC12095364 |
| ○ Supplementary tables | files read; no table could be matched to the samples |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention — arms not resolved
Non-antibiotic pharmaceutical given as the study intervention (metformin design single_arm_before_after · population type2_diabetes · Dapagliflozin (SGLT2i) 10mg/day, 8 weeks
“8-week, single-arm clinical trial” — abstract:40406484 (study level; per-sample arms are in the intervention column below)
longitudinal
12 of 12 people sampled more than once (36 samples; median 3, up to 3 per person) · follow-up median 56 d (max 56 d) · median interval between samples 28 d (time from visit codes mapped to the stated schedule). Schedule stated by the source: “baseline (week 0), week 4, and week 8” (time origin: intervention_start); stated follow-up 56 d.
Each row is one person (11 shown of 12); dots are samples at days since that person's first sample.
Genera, mean relative abundance over 35 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 0 | 0% | ||||
| country | 0 | 0% | ||||
| health_condition | 36 | 100% | 36 | |||
| subject_id | 36 | 100% | 36 | |||
| health_condition_detail | 36 | 100% | 36 |
- Reduced abundance of <i>Fusobacterium</i> signifies cardiovascular benefits of sodium glucose cotransporter 2 inhibitor in type 2 diabetes: a single arm clinical trial. 2025 PMID 40406484 PMC12095364 own_data
Archive description
metagenomic sequencing was conducted on fecal samples from T2DM patients
How this project entered the registry
Classified as human gut / stool shotgun DNA metagenome of age unknown by sonnet_x2 with confidence 0.70. Assay shotgun_dna.
- host run.host_tax_id · “9606”
- body site study.title · “Fecal samples from T2DM patients”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMN47449604 | health_condition | type2_diabetes | R1 | 0.70 | sample.name_rule:library_names | T2DM1-0 |
| SAMN47449604 | health_condition_detail | T2DM | R1 | 0.70 | sample.name_rule:library_names | T2DM1-0 |
| SAMN47449604 | subject_id | 1 | R1 | 0.70 | sample.name_rule:library_names | T2DM1-0 |
Sequencing
36 runs over 36 samples · mean 6.02 Gbp per run (median 6.02 Gbp, total 216.60 Gbp; 36 runs with a base count) · layout PAIRED 36 · platform ILLUMINA 36 · models Illumina NovaSeq 6000 (36) · 97% of runs with a Sandpiper profile · first public 2025-03-30
Authors (12)
Yang S first · Deng J · Weng X · Ma Z · Lin N · Xiao Y · Zuo R · Hu Y · Zheng C · Zeng X · Lin Q · Hou K last
Downloads
PRJNA1238196.csv.gz (1.6 KB) · parquet (69.9 KB) — all 36 samples, every field with route and confidence · PRJNA1238196_determinations.csv.gz (1.2 KB) — 108 evidence rows